Abstract
Hepcidin synthesis is reported to be inadequate according to the body iron store in patients with non-alcoholic fatty liver disease (NAFLD) undergoing hepatic iron overload (HIO). However, the underlying mechanisms remain unclear. We hypothesize that hepatocyte nuclear factor-4α (HNF-4α) may negatively regulate hepcidin expression and contribute to hepcidin deficiency in NAFLD patients. The effect of HNF-4α on hepcidin expression was observed by transfecting specific HNF-4α small interfering RNA (siRNA) or plasmids into HepG2 cells. Both direct and indirect mechanisms involved in the regulation of HNF-4α on hepcidin were detected by real-time PCR, Western blotting, chromatin immunoprecipitation (chIP), and reporter genes. It was found that HNF-4α suppressed hepcidin messenger RNA (mRNA) and protein expressions in HepG2 cells, and this suppressive effect was independent of the potential HNF-4α response elements. Phosphorylation of SMAD1 but not STAT3 was inactivated by HNF-4α, and the SMAD4 response element was found essential to HNF-4α-induced hepcidin reduction. Neither inhibitory SMADs, SMAD6, and SMAD7 nor BMPR ligands, BMP2, BMP4, BMP6, and BMP7 were regulated by HNF-4α in HepG2 cells. BMPR1A, but not BMPR1B, BMPR2, ActR2A, ActR2B, or HJV, was decreased by HNF-4α, and HNF4α-knockdown-induced stimulation of hepcidin could be entirely blocked when BMPR1A was interfered with at the same time. In conclusion, the present study suggests that HNF-4α has a suppressive effect on hepcidin expression by inactivating the BMP pathway, specifically via BMPR1A, in HepG2 cells.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Hepcidin is a liver-derived peptide hormone and plays a key role in iron homeostasis by negatively regulating intestinal iron absorption and iron release from macrophages [1]. Hepatic iron overload (HIO) is frequently observed in patients with non-alcoholic fatty liver disease (NAFLD) [2, 3] and has been confirmed to promote disease progression by increasing hepatic fibrosis and liver cholesterol synthesis [4, 5]. Dysregulation of hepcidin was frequently observed in patients with NAFLD with HIO [6–8]. Although serum or liver hepcidin was found to be increased in NAFLD patients, the production of hepcidin that was normalized to serum ferritin or hepatic iron score (HIS) was still insufficient compared to the elevation of body iron stores [9, 10]. Impaired hepcidin response was considered to be closely related with the severe form of HIO in NAFLD [11, 12] and has also been proved to play an important role in HIO in some other metabolic diseases, such as type 2 diabetes [13, 14]. However, the mechanisms underlying hepcidin deficiency in NAFLD patients remain elusive.
Hepatocyte nuclear factor-4α (HNF-4α) is a liver-enriched transcription factor that is critical in lipid and glucose metabolism. Saturated fatty acid, the most important independent risk factor of NAFLD [15–17], can significantly stimulate HNF-4α expression [18–20]. The protein level of HNF-4α was also found significantly increased in mice with leptin-deficient (ob/ob) or diet-induced obesity mimicking the onset of NAFLD [21, 22]. What is more, Courselaud et al. [23] found that HEPC transcripts were increased in liver-specific HNF4α-null mice. All these findings suggest that HNF-4α may play a putative role in relative hepcidin deficiency in NAFLD patients. However, the molecular mechanism underlying how HNF-4α regulates hepcidin expression remains unclear.
The aim of the present study was to dissect the effect of HNF-4α on hepcidin expression in HepG2 cells in vitro and further clarify its molecular mechanisms, in an attempt to gain deeper insights into the etiology of hepcidin deficiency in NAFLD patients with HIO so as to provide a potential new therapeutic target.
Materials and Methods
Cell Culture, Treatment, and Transfection of siRNA and Plasmids
The human hepatoma cell line HepG2 (Chinese Academy of Sciences, Shanghai, China) was grown at 37 °C in a mixture of high glucose DMEM medium (Hyclone, USA) supplemented with 10 % fetal bovine serum (FBS) (Hyclone, USA) (v:v), 100 IU/ml penicillin, and 50 μg/ml streptomycin sulfate (Hyclone, USA). For HNF-4α, SMAD4, or/and BMPR1A silencing, cells were transferred to 6-well plates and transfected with HNF-4α, SMAD4, or/and BMPR1A siRNA products (sc-35573, sc-92315, and sc-40216, Santa Cruz Biotechnology, USA) that generally consist of pools of three to five target-specific 19–25 nt siRNAs designed to knockdown gene expression or a negative invalid control siRNA in the presence of lipofectamine RNAiMAX in normal growth medium with antibiotics, according to the manufacturer’s instructions (Invitrogen, USA). After a 12 h transfection, the medium was replaced and cells were incubated for additional 36 h. For HNF-4α over-expression, HepG2 cells were seeded in 6-well plates and transfected with 2 μg HNF-4α or empty plasmids (Genephorma, Shanghai, China) in the presence of FuGENE HD transfection reagent (E2311, Promega, Madison, WI, USA) and then incubated for 12 h, then the medium was replaced and cells were incubated for additional 36 h. For BMP inhibitor experiments, HepG2 cells were transfected with HNF-4α siRNA in the presence or absence of the BMP inhibitor LDN193189 (100 nM; Selleck Chemicals, Houston, USA). After a 12 h transfection, the medium was replaced and cells were incubated for additional 36 h with or without additional LDN193189.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (chIP) assay was performed using a commercially available kit (Upstate Biotechnology, Lake Placid, NY, USA) as described by Diedra M [24]. The antibody against HNF-4α was purchased from Santa Cruz (CA, USA) and SMAD4 and STAT3 from CST (Cell Signaling Techno logy, Danvers, MA, USA). The primer sequences used for PCR were as follows: Hepc forward 5′-CGCT CTGT TCCC GCTT AT-3′ and Hepc reverse 5′-CGAG TGAC AGTC GCTT TTAT G-3′ that amplified 129 bp of human hepcidin promoter containing the response elements of SMAD4, STAT3, and HNF-4α (the proximal one); Hepc forward 5′-ATGGG GTCTC CCTAT GTTGC-3′ and Hepc reverse 5′- CCTTG AGATG TGGCT CTGGT AA-3′ that amplified 184 bp of human hepcidin promoter containing the response element of HNF-4α (the distal one).
Generation of Hepcidin Promoter Plasmid Constructs, Cell Transfection, and Luciferase Reporter Assays
pGL3-basic luciferase reporter (Promega, Southampton, UK) with full-length human hepcidin promoter was generated by obtaining genomic DNA from HepG2 cells and cloning the proximal 942 bp of human HAMP promoter into the pGL3-basic luciferase reporter vector, as described by Courselaud et al. [23]. Site-directed mutagenesis (Quickchange II, Stratagene, Stockport, UK) on putative BMPs response elements was performed as described by Ling et al. [25] and the putative HNF-4α response element was depleted according to Courselaud et al. [23]. HepG2 cells were transferred to 48-well plates and transfected with empty pGL3-basic vectors, certain HAMP reporter constructs, and HNF-4α plasmids (Genephorma, Shanghai, China) using FuGENE HD Transfection Reagent (Promega, Madison, WI, UK) according to the manufacturer’s instructions. To normalize the transfection efficiency, an internal control pRL-SV40 Renilla luciferase plasmids (Promega, Southampton, UK) was co-transfected alongside the HAMP constructs in a 1:200 ratio in serum-free medium. After a 48 h equilibration, luciferase activity was determined in triplicate in at least three independent experiments using the Dual Luciferase Reporter Assay, according to the manufacturer’s instructions (Promega, Southampton, UK).
RNA Isolation and Real-Time Quantitative PCR
Real-time qPCR was used to analyze HNF-4α and hepcidin mRNA levels in HepG2 cells. Total RNA was extracted from HepG2 cells using a single step extraction method and TRIzol reagent (Invitrogen, USA), as previously described [26]. Total RNA was reverse-transcribed using RT regent Kit (PrimerscriptTM, TAKARA, Japan). Real-time qPCR was performed in 1× Universal Master Mix (Applied Biosystems, USA) with gene-specific primers by the ABI Prism 7300 Sequence Detection System (Applied Biosystems, USA), and mRNA levels of specific genes were normalized to the β-actin levels of the same sample.
Western Blotting
HepG2 cells were washed twice in Hank’s balanced salt solution and homogenized in lysis buffer for the preparation of whole protein extracts. NE-PER Reagents (Pierce Biotechnology, Rockford, IL, USA) was used to extract nuclear and cytosolic proteins according to the manufacturer’s instructions. Protein concentrations were determined using the BCA Protein Assay kit (Pierce Biotechnology). Cell lysates (30 μg) were loaded and then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (10 % ~ 15 %). After electrophoresis, proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA) using the wet Trans-Blot Cell (Bio-Rad Laboratories, Hercules, CA, USA). Then, the membranes were blocked with 5 % (w/v) nonfat milk powder in TBS/T (0.5 % Tween 20 in 1× Tris-buffered saline) for 2 h at room temperature. The blots were then incubated overnight at 4 °C with primary antibodies, followed by incubation with an IRDye 800CW-conjugated secondary antibody and detection with LI-COR imaging system (LI-COR Biosciences). The following primary antibodies were used: HNF-4α (Santa Cruz, USA; 1:500 dilution), hepcidin (ab30760, Abcam, UK; 1:100 dilution), SMAD1 (Cell Signaling Technology, USA; 1:1000 dilution), pSMAD1/5/8 (Cell Signaling Technology, USA; 1:1000 dilution), SMAD4 (BBI, China; 1:1000 dilution), STAT3 (Cell Signaling Technology, USA; 1:1000 dilution), pSTAT3 (Cell Signaling Technology, USA; 1:1000 dilution), BMPR1A (Epitomics, USA; 1:500 dilution), BMPR1B (Abcam, UK; 1:500 dilution), BMPR2 (Epitomics, USA; 1:500 dilution), ActR2A (BBI, China; 1:1000 dilution), ActR2B (BBI, China; 1:1000 dilution), HJV (Abcam, UK; 1:100 dilution), Id1 (Santa Cruz, USA; 1:200 dilution), and β-actin (Bioworld, USA; 1:5000 dilution). The immunoreactive bands were quantitated by densitometric scanning. After a wash with TBS/T containing 0.5 % Tween 20, the blots with monoclonal antibodies were incubated with peroxidase-conjugated affinipure rabbit anti-goat or goat anti-rabbit immunoglobulin G (Jackson ImmunoReasch Laboratories, USA; 1:4000 dilution). Peroxidase-conjugated antibodies were detected by the enhanced chemiluminescence (ECL) method (Amersham). Signals quantitated by densitometry were normalized to β-actin levels or, in the case of phosphoproteins, to the total levels of the same protein.
Statistics
Values are represented as mean ± standard error mean (S.E.M.). Statistical analysis was performed using the Statview software (SAS Institute Inc., SAS campus drive, USA). Statistical difference between two groups was assessed by the Independent t test. One-way ANOVA, followed by LSD t post hoc test, was performed to analyze the difference between the three or more groups. P < 0.05 is considered statistically significant.
Results
HNF-4α Inhibits Hepcidin Expression in HepG2 Cells
To directly evaluate the effect of HNF-4α on hepcidin expression, HNF-4α siRNA or plasmid was transfected into HepG2 cells, and hepcidin mRNA and protein levels were detected by real-time qPCR and Western Blot. Compared with the blank control group, hepcidin mRNA and protein levels were both markedly increased when HNF-4α was knocked down (for hepcidin, si-HNF4α vs. control, p < 0.01) (Fig. 1a, c) and significantly reduced when HNF-4α was over-expressed (for hepcidin, oe-HNF4α vs. control, p < 0.001 or p < 0.01) (Fig. 1b, c).
HNF4α-Induced Reduction of Hepcidin is not Dependent on its Potential Response Elements on Hepcidin Promoter
Knowing that two potential response elements were reported on the flanking region of human HEPC gene [23], we first verified whether HNF-4α could bind to human HEPC promoter through chromatin immunoprecipitation (chIP) experiments. Our data showed that HNF-4α bound to human hepcidin promoter through the proximal binding site but not the distal one (for distal binding site, potential HRE1; for proximal binding site, potential HRE2) (Fig. 2a). Next, we observed the role of the chIP-verified response element in the HNF4α-induced reduction of hepcidin through experiments with reporter genes. HepG2 cells were co-transfected with human hepcidin promoter with or without the HNF-4α binding sites and plasmids encoding HNF-4α (for wild-type HEPC promoter, HAMP; for HEPC promoter with depletion of HNF-4α binding site, ΔHNF-4α) (Fig. 2b). HNF-4α plasmids showed an obvious inhibitory effect on the luciferase activities of the wild full-length hepcidin promoter (HAMP + HNF-4α vs. HAMP, p < 0.001) (Fig. 2b). Furthermore, depletion of the HNF-4α binding sites significantly suppressed the basal level of the hepcidin promoter activity (ΔHNF-4α vs. HAMP, p < 0.001) (Fig. 2b), but showed no blocking effect on the HNF4α-induced reduction (ΔHNF-4α + HNF-4α vs. ΔHNF-4α, p < 0.001) (Fig. 2b).
HNF-4α negatively Regulates Hepcidin by Inactivating BMP but not IL-6 Pathway
STAT3 and SMADs are known to mediate hepcidin response to IL-6 and BMPs, respectively. To determine whether these two novel pathways were involved in HNF4α-induced hepcidin repression, we observed the effect of HNF-4α on the total and/or phosphorylated protein levels of STAT3, SMAD1, and SMAD4. It was found that the phosphorylation of SMADs was markedly inhibited by HNF-4α plasmids and markedly enhanced when HNF-4α was knocked down by specific siRNA (oe-HNF4α vs. control, p < 0.05; si-HNF4α vs. control, p < 0.05) (Fig. 3), without altering the total level of SMAD1 and SMAD4 (p > 0.05) (Fig. 3). Besides, no significant alteration was found in the total or phosphorylated protein levels of STAT3 when HNF-4α was interfered with or over-expressed (p > 0.05) (Fig. 3).
In order to further verify the role of the BMP signaling pathway in HNF4α-mediated hepcidin suppression, chIP, reporter gene assay, and co-transfection with HNF-4α and SMAD4 siRNA was performed (for wild-type HEPC promoter, HAMP; for HEPC promoter with mutation on SMAD4 binding site, ΔSMAD4; for HNF-4α silence, ΔH; for SMAD4 silence, ΔS; for co-silence, ΔH + S). The results of chIP showed that the amount of SMAD4 binding to hepcidin promoter was increased markedly in HepG2 cells transfected with HNF-4α siRNA (SI) and decreased obviously when HNF-4α was over-expressed (OE) by encoding plasmids (SMAD4: SI vs. control, p < 0.01; OE vs. Control, p < 0.001) (Fig. 4a), but the amount of STAT3 remained unchanged under both of the above conditions (Fig. 4a). The luciferase activity of hepcidin promoter with mutation SMAD4 binding site was no longer decreased and significantly increased when HNF-4α plasmids were co-transfected (HAMP + HNF-4α vs. HAMP, p < 0.001; ΔSMAD4 + HNF-4α vs. ΔSMAD4, p < 0.001) (Fig. 4b). The expression of hepcidin in HepG2 cells with low levels of HNF-4α was elevated markedly, which could be entirely blocked by co-transfection of SMAD4 siRNA (ΔH vs. control, p < 0.05; ΔH + S vs. ΔS, p > 0.05) (Fig. 4c).
In addition, we also found Id1, another well-characterized transcriptional target of BMP-activated SMADs, was significantly inhibited by HNF-4α over-expression and obviously upregulated when HNF-4α was knocked down (si-HNF4α vs. control, p < 0.001; oe-HNF4α vs. control, p < 0.001) (Supplemental Data, Fig. 1). Besides, we also showed that BMP2-stimulated hepcidin expression disappeared when HNF-4α was over-expressed in HepG2 cells (OE + BMP2 vs. control, p < 0.001) (Supplemental Data, Fig. 2).
The Suppressive Effect of HNF-4α on BMP Pathway and Hepcidin is Specifically Mediated by BMPR1A
Protein levels of BMP receptors (BMPR1A, BMPR1B, BMPR2, ActR2A, and ActR2B) [27] and the co-receptor HJV [1] were analyzed by Western blot to better clarify how HNF-4α repressed the activation of the BMP pathway, or more precisely, the phosphorylation of SMAD1. The results showed that the silencing of HNF-4α increased the level of BMPR1A, while over-expression decreased it (si-HNF4α vs. control, p < 0.01; oe-HNF4α vs. control, p < 0.01) (Fig. 5), without significantly altering BMPR1B, BMPR2, ActR2A, ActR2B, and HJV (p > 0.05) (Fig. 5).
To better investigate the role of BMPR type I receptor and/or BMPR1A in the suppressive effect of HNF-4α on hepcidin, we observed the effect of BMP type I receptor inhibitor, LDN193189, on HNF-4α regulation of hepcidin, and also the hepcidin expression in HepG2 cells co-transfected with HNF-4α and BMPR1A siRNA (for BMP inhibitor LDN193189, L; for HNF-4α silence in the presence of LDN193189, L + ΔH; for HNF-4α silence, ΔH; for BMPR1A silence, ΔB; and for co-silence, ΔH + B) (Fig. 6a, b). It was found that the upregulation of hepcidin by HNF-4α silence could be entirely blocked by either administration of LDN193189 or knocking down BMPR1A (ΔH vs. Control, p < 0.05; L + ΔH vs. L, p > 0.05; ΔH vs. Control, p < 0.05; ΔH + B vs. ΔB, p > 0.05) (Fig. 6a, b). In addition, we also found that neither BMPR1A ligands nor intracellular inhibitory SMADs could be regulated by HNF-4α (p > 0.05) (Supplemental Data, Figs. 3 and 4).
Discussion
Hepcidin is a liver-derived peptide hormone that plays a key role in iron homeostasis by negatively regulating body iron stores [1]. It was reported that, although elevated, the production of hepcidin mRNA in NAFLD patients with HIO was still insufficient [9, 10], which is believed to play an important role in the occurrence of HIO [9, 15]. However, the mechanism underlying the impairment to hepcidin expression remains unclear. The orphan nuclear receptor HNF-4α is an essential transcription factor and master regulatory protein of lipid and glucose metabolism [28, 29]. In the present study, we demonstrated that HNF-4α inhibited the activity of the BMP pathway specifically through BMPR1A and negatively regulated hepcidin expression in HepG2 cells, providing a probable new link between HNF-4α, or furthermore, lipid metabolic disorder and iron metabolism.
We found that the expression of hepcidin protein was significantly suppressed by HNF-4α plasmids and markedly elevated when HNF-4α expression was interfered with by specific siRNA, suggesting that HNF-4α had an inhibitory effect on hepcidin synthesis. The same result was also found in the mRNA level of hepcidin, furthermore, implying that the regulatory effect of HNF-4α on hepcidin probably occurred at the transcriptional level. Knowing that HNF-4α has two potential binding sites in the HEPC 5′-flanking promoter region [23], we then evaluated whether HNF-4α could bind to the hepcidin and play a direct inhibitory effect on hepcidin transcription. It was found that HNF-4α could bind to the proximal potential binding site in the human hepcidin promoter. However, the data of reporter gene experiments further demonstrated that HNF-4α induced reduction on fluorescence activity of hepcidin promoter could not be blocked by deletion of the chIP-verified HNF4-binding sites, suggesting that HNF-4α may indirectly, but not directly, suppress the transcriptional activity of hepcidin. In addition, we were surprised to find that the fluorescence activity of hepcidin promoter showed a significant moderate decrease, but not increase, after the knockout of HNF-4α response element, implying that the direct effect of HNF-4α on hepcidin might be positive but not negative, which is consistent with the regulatory effect of HNF-4α on many other target proteins involved in lipid and glucose metabolism [30]. These data strongly suggest that, besides a direct positive effect of HNF-4α on hepcidin transcription, there exists a dominant indirect mechanism involved in the HNF-4α-induced hepcidin reduction.
STAT3 and SMADs are novel transcription regulators of hepcidin and mediate its response to IL-6 and BMPs. In the present study, we found that only the level of pSMAD1/5/8 protein was significantly suppressed by HNF-4α and obviously stimulated when HepG2 was transfected with HNF-4α siRNA. STAT3, pSTAT3, SMAD1, and SMAD4 all remained unchanged when HNF-4α was silenced or over-expressed, suggesting that HNF-4α reduced hepcidin specifically via inactivation of BMP pathway. Our results also demonstrated that the binding activity of SMAD4 to human hepcidin promoter was dramatically enhanced or suppressed under the condition of HNF-4α knockdown or over-expressed, but no significant change was observed in the binding activity of STAT3. These results further demonstrated that it was BMP but not IL-6 pathway that may be involved in the mechanism underlying the inhibitory effect of HNF-4α on hepcidin.
Besides, we also found that the fluorescence activity of human hepcidin promoter with mutation SMAD4-binding site was no longer decreased in response to HNF-4α plasmids, once again suggesting that the BMP pathway was essential for the suppressive effect of HNF-4α on hepcidin. The increase of fluorescence activity of human hepcidin promoter with mutation SMAD4-binding site is consistent with our previous finding that there might be a direct stimulatory effect of HNF-4α on hepcidin transcription through potential response elements; however, it was much weaker compared with the negative one mediated by BMP pathway and therefore could be observed only when BMP pathway was blocked. On the basis of the above results, we further confirmed the role of BMP pathway by finding that HNF-4α siRNA-induced elevation of hepcidin totally disappeared in the absence of SMAD4, better supporting the critical role of BMP pathway in HNF-4α regulation on hepcidin.
To clarify the mechanism underlying the inactivation of BMP pathway by HNF-4α, we first observed the effect of HNF-4α on BMP receptors and their co-receptor HJV and found that only BMPR1A could be regulated by HNF-4α and was markedly decreased, implying that BMPR1A might be involved in the reduction of hepcidin induced by HNF-4α. LDN193189, a BMP type I receptor inhibitor, was proved to totally blocked hepcidin elevation induced by HNF-4α knockdown in our present study, and we also found that silencing HNF-4α could not further stimulate hepcidin expression when BMPR1A was knocked down at the same time. Our results indicated that the suppressive effect of HNF-4α on BMP pathway and hepcidin expression was dependent on BMP type I receptor, and more precisely, BMPR1A. BMPR1A, and 1B share different bio-functions in vivo. BMPR1A was found to play a specific role in Mullerian duct regression [31], heart morphogenesis [32], and growth control of colon epithelial cells [33] while BMPR1B was considered essential in reproductive function [34]. It was even reported that BMPR1A and BMPR1B signaling exerted opposing effects on gliosis after spinal cord injury [35]. BMP1A and 1B also showed different affinity to their upstream ligands. For instance, BMPR1B bound more efficiently to GDF-15 [36] and BMP7 [37]. All these findings illustrate that BMPR1A and 1B have significant distinction on their response to upstream factors and mediation of downstream pathways, which might be part of the reason why HNF-4α only showed its regulatory effect on BMPR1A.
The molecular mechanism underlying the repression of BMPR1A by HNF-4α remains undetermined. In silico analysis of BMPR1A, promoter was previously performed with only SP1 response elements were detected [38]. A subsequent study proved that it positively regulated transcription of BMPR1A [39], implying that SP1 may, to some extent, participate in the regulation of HNF-4α on BMPR1A. Functional synergism of HNF-4α and Sp1 on the human apolipoprotein CIII (apoCIII) promoter was found in other studies [40, 41], failing to support a possible negative regulatory effect of HNF-4α on BMPR1A expression. Although the interaction of HNF-4α with SP1 in their co-regulation of blood coagulation factor X was previously reported to be mutually exclusive, a minor overlap of their binding sites was eventually found [42]. In addition, no binding site for HNF-4α was identified in the BMPR1A promoter and other type I BMPR. These results imply that HNF-4α might not repress BMR1A directly or through interaction with SP1, and therefore, the mechanism underlying the effect of HNF-4α on BMPR1A expression requires further study.
It was recently reported that miR-122 is positively regulated by HNF-4α [43] and also plays a direct inhibitory role in hepcidin transcription via its response elements on the promoter [44]. These findings imply that miR-122 may also, to some extent, be involved in the suppressive effect of HNF-4α on hepcidin, although further evidence for this conclusion is required. BMPR1A mRNA was also reported to have been decreased by miR-122; however, no significant response of pSMAD1/5/8 to miR-122 was determined in the same study [44], suggesting that miR-122 may not be involved in the regulation of HNF-4α on BMPR1A.
In summary, our study reports HNF-4α to inhibit hepcidin expression by specifically suppressing BMPR1A in HepG2 cells and thus elucidating a likely novel mechanism of hepcidin regulation. Since HNF-4α is significantly stimulated by several risk factors of NAFLD, such as saturated fatty acids, our study assists in explaining the relative deficiency of hepcidin in NAFLD.
References
Fleming MD (2008) The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program:151–158
Sikorska K, Stalke P, Romanowski T, Rzepko R, Bielawski KP (2013) Liver steatosis correlates with iron overload but not with HFE gene mutations in chronic hepatitis C. Hepatobiliary Pancreat Dis Int 12:377–384
Nelson JE, Klintworth H, Kowdley KV (2012) Iron metabolism in nonalcoholic fatty liver disease. Curr Gastroenterol Rep 14:8–16
Datz C, Felder TK, Niederseer D, Aigner E (2013) Iron homeostasis in the metabolic syndrome. Eur J Clin Investig 43:215–224
O'Brien J, Powell LW (2012) Non-alcoholic fatty liver disease: is iron relevant? Hepatol Int 6:332–341
Valenti L, Rametta R, Dongiovanni P, Motta BM, Canavesi E, Pelusi S, Pulixi EA, Fracanzani AL, Fargion S (2012) The A736 V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS One 7:e48804
Dongiovanni P, Fracanzani AL, Fargion S, Valenti L (2011) Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 55:920–932
Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, Strasser M, Datz C, Weiss G (2008) Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 87:1374–1383
Tsuchiya H, Ebata Y, Sakabe T, Hama S, Kogure K, Shiota G (2013) High-fat, high-fructose diet induces hepatic iron overload via a hepcidin-independent mechanism prior to the onset of liver steatosis and insulin resistance in mice. Metabolism 62:62–69
Ravasi G, Pelucchi S, Trombini P, Mariani R, Tomosugi N, Modignani GL, Pozzi M, Nemeth E, Ganz T, Hayashi H, Barisani D, Piperno A (2012) Hepcidin expression in iron overload diseases is variably modulated by circulating factors. PLoS One 7:e36425
Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, Minami M, Itoh Y, Okanoue T, Yoshikawa T (2009) Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res 39:366–373
Barisani D, Pelucchi S, Mariani R, Galimberti S, Trombini P, Fumagalli D, Meneveri R, Nemeth E, Ganz T, Piperno A (2008) Hepcidin and iron-related gene expression in subjects with Dysmetabolic hepatic iron overload. J Hepatol 49:123–133
Sam AH, Busbridge M, Amin A, Webber L, White D, Franks S, Martin NM, Sleeth M, Ismail NA, Mat Daud N, Papamargaritis D, Le Roux CW, Chapman RS, Frost G, Bloom SR, Murphy KG (2013) Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. Diabetic MED 30:1495–1499
Fernández-Real JM, Equitani F, Moreno JM, Manco M, Ortega F, Ricart W (2009) Study of circulating prohepcidin in association with insulin sensitivity and changing iron stores. J Clin Endocrinol Metab 94:982–988
Carvalhana S, Machado MV, Cortez-Pinto H (2012) Improving dietary patterns in patients with nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 15:468–473
Gentile CL, Frye MA, Pagliassotti MJ (2011) Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. Biofactors 37:8–16
Gentile CL, Pagliassotti MJ (2008) The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 19:567–576
Hertz R, Kalderon B, Byk T, Berman I, Za'tara G, Mayer R, Bar-Tana J (2005) Thioesterase activity and acyl-CoA/fatty acid cross-talk of hepatocyte nuclear factor-4alpha. J Biol Chem 280:24451–24461
Pégorier JP, Le May C, Girard J (2004) Control of gene expression by fatty acids. J Nutr 134:2444S–2449S
Jazurek M, Dobrzyń P, Dobrzyń A (2008) Regulation of gene expression by long-chain fatty acids. Postepy Biochem 54:242–250
De Souza CT, Frederico MJ, da Luz G, Cintra DE, Ropelle ER, Pauli JR, Velloso LA (2010) Acute exercise reduces hepatic glucose production through inhibition of the Foxo1/HNF-4α pathway in insulin resistant mice. J Physiol 588:2239–2253
Souza Pauli LS, Ropelle EC, de Souza CT, Cintra DE, da Silva AS, de Almeida Rodrigues B, de Moura LP, Marinho R, de Oliveira V, Katashima CK, Pauli JR, Ropelle ER (2014) Exercise training decreases mitogen-activated protein kinase phosphatase-3 expression and suppresses hepatic gluconeogenesis in obese mice. J Physiol 592:1325–1340
Courselaud B, Pigeon C, Inoue Y, Inoue J, Gonzalez FJ, Leroyer P, Gilot D, Boudjema K, Guguen-Guillouzo C, Brissot P, Loréal O, Ilyin G (2002) C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem 277:41163–41170
Diedra M, Nancy C (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood 108:3204–3209
Ling C, Wang Y, Zhang Y, Ejjigani A, Yin Z, Lu Y, Wang L, Wang M, Li J, Hu Z, Aslanidi GV, Zhong L, Gao G, Srivastava A, Ling C (2014) Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum Gene Ther 25:1023–1034
Wang LN, Wang Y, Lu Y, Yin ZF, Zhang YH, Aslanidi GV, Srivastava A, Ling CQ, Ling C (2014) Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. J Intern Med 12:20–34
Dijke P, Korchynskyi O, Valdimarsdottir G, Goumans MJ (2003) Controlling cell fate by bone morphogenetic protein receptors. Mol Cel Endo 211:105–113
Watt AJ, Garrison WD, Duncan SA (2003) A central regulator of hepatocyte differentiation and function. Hepatology 37:1249–1253
Hirota K, Sakamaki J, Ishida J, Shimamoto Y, Nishihara S, Kodama N, Ohta K, Yamamoto M, Tanimoto K, Fukamizu A (2008) A combination of HNF-4 and Foxo1 is required for reciprocal transcriptional regulation of glucokinase and glucose-6-phosphatase genes in response to fasting and feeding. J Biol Chem 283:32432–32441
Sladek FM (1993) Orphan receptor HNF-4 and liver-specific gene expression. Receptor 3:223–232
Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR (2002) Requirement of Bmpr1a for Müllerian duct regression during male sexual development. Nat Genet 32:408–410
Gaussin V, Van de Putte T, Mishina Y, Hanks MC, Zwijsen A, Huylebroeck D, Behringer RR, Schneider MD (2002) Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK-3. Proc Natl Acad Sci U S A 99:2878–2883
Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, Velculescu VE, Traverso G, Vogelstein B (2001) Germline mutations of the gene encoding bone morphogenetic protein receptor 1 A in juvenile polyposis. Nat Genet 28:184–187
Yi SE, LaPolt PS, Yoon BS, Chen JY, Lu JK, Lyons KM (2001) The type I BMP receptor BmprIB is essential for female reproductive function. Proc Natl Acad Sci U S A 98:7994–7999
Sahni V, Mukhopadhyay A, Tysseling V, Hebert A, Birch D, Mcguire TL, Stupp SI, Kessler JA (2010) BMPR1a and BMPR1b signaling exert opposing effects on gliosis after spinal cord injury. J Neur 30:1839–1855
Nishitoh H, Ichijo H, Kimura M, Matsumoto T, Makishima F, Yamaguchi A, Yamashita H, Enomoto S, Miyazono K (1996) Identification of types I and II serine/threonine kinase receptors for growth/differentiation factor-5. J Biol Chem 271:21345–21352
Macias-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL (1998) Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK-2. J Biol Chem 273:25628–25636
Calva-Cerqueira D, Dahdaleh FS, Woodfield G, Chinnathambi S, Nagy PL, Larsen-Haidle J, Weigel RJ, Howe JR (2010) Discovery of the BMPR1A promoter and germline mutations that cause juvenile polyposis. Hum Mol Genet 19:4654–4662
Dahdaleh FS, Carr JC, Calva D, Howe JR, Howe JR (2011) SP1 regulates the transcription of BMPR1A. J Surg Res 171:e15–e20
Talianidis I, Tambakaki A, Toursounova J, Zannis VI (1995) Complex interactions between SP1 bound to multiple distal regulatory sites and HNF-4 bound to the proximal promoter lead to transcriptional activation of liver-specific human APOCIII gene. Biochemistry 34:10298–10309
Kardassis D, Falvey E, Tsantili P, Hadzopoulou-Cladaras M, Zannis V (2002) Direct physical interactions between HNF-4 and Sp1 mediate synergistic transactivation of the apolipoprotein CIII promoter. Biochemistry 41:1217–1228
Hung HL, High KA (1996) Liver-enriched transcription factor HNF-4 and ubiquitous factor NF-Y are critical for expression of blood coagulation factor X. J Biol Chem 271:2323–2331
Li ZY, Xi Y, Zhu WN, Zeng C, Zhang ZQ, Guo ZC, Hao DL, Liu G, Feng L, Chen HZ, Chen F, Lv X, Liu DP, Liang CC (2011) Positive regulation of hepatic miR-122 expression by HNF4α. J Hepatol 55:602–611
Castoldi M, Vujic Spasic M, Altamura S, Elmén J, Lindow M, Kiss J, Stolte J, Sparla R, D'Alessandro LA, Klingmüller U, Fleming RE, Longerich T, Gröne HJ, Benes V, Kauppinen S, Hentze MW, Muckenthaler MU (2011) The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest 121:1386–1396
Matak P, Chaston TB, Chung B, Srai SK, McKie AT, Sharp PA (2009) Activated macrophages induce hepcidin expression in HuH7 hepatoma cells. Haematologica 94:773–780
Acknowledgments
This study was supported by the funds from the National Natural Science Foundation of China (81273053). There are no potential conflicts of interest relevant to this article.
Author Contributions
Min Li, who designed the concept of the study, made critical revisions of the manuscript and was responsible for obtaining the funding. Wencai Shi and Heyang Wang, who designed the study, provided technical or material support, participated in data acquisition, analysis and interpretation, drafted the manuscript, and performed the statistical analysis. Xuan Zheng, Xin Jiang, Zheng Xu, and Hui Shen participated in data acquisition and technical support. Min Li is the guarantor of this article and, as such, has full access to all the data in the study and is responsible for the integrity of the data and the accuracy of the data analysis.
We also thank Shunxing Zhang, the professor of English Department of Second Military Medical University, for his work on the modifications on our revision manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Wencai Shi and Heyang Wang contribute equally to this work.
Electronic supplementary material
ESM 1
HNF-4α reduces Id1 expression in HepG2 cells. HepG2 cells were transferred to 6-well plates and incubated with growth medium containing negative invalid control siRNA (Con) or specific HNF-4α siRNA (si-HNF4α) (A), empty control plasmids (Con) or plasmids encoding HNF-4α (oe-HNF4α) (B) for 12 h and normal growth medium for additional 36 h. Id1 protein was measured by Western blotting. ***, significantly different from control, p < 0.001. Values are expressed as mean ± S.E.M., determined in three independent experiments. Statistical difference between two groups was assessed by the Independent-t test. (DOCX 219 kb)
ESM 2
HNF-4α blocks BMP2-induced stimulation of hepcidin in HepG2 cells. HepG2 cells were transfected with 2 μg HNF-4α or empty plasmids, and then incubated for 48 h, with or without 2 μg/ml recombinant human BMP2 in the last 8 h. Protein levels of HNF-4α, hepcidn and β-actin were detected by Western blotting. ***, significantly different from control, p < 0.001. Values are expressed as mean ± S.E.M., determined in three independent experiments. Statistical difference between groups was assessed by one-way ANOVA followed by LSD t post hoc test. (DOCX 83 kb)
ESM 3
HNF-4α has no effect on the synthesis of novel BMPR1A ligands. Protein levels of BMP2, BMP4, BMP6, and BMP7 were detected by Western blotting (BMP2: Proteintech, USA; 1:1000 dilution; BMP4: BBI, China; 1:1000 dilution; BMP6: BBI, China; 1:1000 dilution; BMP7: Proteintech, USA; 1:1000 dilution) in HepG2 cells transfected with invalid negative control siRNA (Con) or specific HNF-4α siRNA (si-HNF4α), or in empty HepG2 cells transfected with empty control plasmids (Con) or plasmids encoding HNF-4α (oe-HNF4α). Values are expressed as mean ± S.E.M., determined in three independent experiments. Statistical difference between two groups was assessed by the Independent-t test. (DOCX 278 kb)
ESM 4
HNF-4α has no effect on the expression of intracellular inhibitory SMADs. Protein levels of SMAD6 and SAMD7 were detected by Western blotting (SMAD6: Bioworld, USA; 1:500 dilution; SMAD7: BBI, China; 1:1000 dilution) in HepG2 cells transfected with invalid negative control siRNA(Con) or specific HNF-4α siRNA (si-HNF4α), or in empty HepG2 cells transfected with empty control plasmids (Con) or plasmids encoding HNF-4α (oe-HNF4α). Values are expressed as mean ± S.E.M., determined in three independent experiments. Statistical difference between the two groups was assessed by the Independent-t test. (DOCX 165 kb)
Rights and permissions
About this article
Cite this article
Shi, W., Wang, H., Zheng, X. et al. HNF-4alpha Negatively Regulates Hepcidin Expression Through BMPR1A in HepG2 Cells. Biol Trace Elem Res 176, 294–304 (2017). https://doi.org/10.1007/s12011-016-0846-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12011-016-0846-5